Insider Transactions in Q1 2025 at Ironwood Pharmaceuticals Inc (IRWD)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2025
|
Gregory S. Martini Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,052
-6.15%
|
$12,052
$1.76 P/Share
|
|
Feb 10
2025
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
38,938
-8.71%
|
$38,938
$1.76 P/Share
|
|
Feb 10
2025
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
122,222
+21.47%
|
-
|
|
Feb 10
2025
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
41,269
-6.93%
|
$41,269
$1.76 P/Share
|
|
Feb 10
2025
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
133,333
+18.3%
|
-
|
|
Feb 10
2025
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,048
-4.13%
|
$12,048
$1.76 P/Share
|
|
Feb 10
2025
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
139,064
-10.7%
|
$139,064
$1.76 P/Share
|
|
Jan 27
2025
|
Gregory S. Martini Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
111,111
+36.2%
|
-
|
|
Jan 27
2025
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
133,333
+31.37%
|
-
|
|
Jan 17
2025
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
48,224
+9.45%
|
-
|
|
Jan 17
2025
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
147,354
+10.18%
|
-
|
|
Jan 17
2025
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,187
+11.01%
|
-
|